Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives

References

• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. [2009 Oct 1];64(10):1417–1426. doi: 10.1111/j.1398-9995.2009.02179.x
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. [2022 Mar 1];77(3):734–766. doi: 10.1111/all.15090
   PubMed Web of Science ®Google Scholar
• Gabrielli S, Mule P, Prosty C, et al. Validation of UAS7 among children with chronic spontaneous urticaria. J Allergy Clin Immunol Pract. [2022 Jul 1];10(7):1927–1929.e1. doi: 10.1016/j.jaip.2022.02.033
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Munoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. [2022 Jun 1];149(6):1819–1831. doi: 10.1016/j.jaci.2022.04.010
   PubMed Web of Science ®Google Scholar
• Asero R, Ferrer M, Kocaturk E, et al. Chronic spontaneous urticaria: the role and relevance of Autoreactivity, autoimmunity, and Autoallergy. J Allergy Clin Immunol Pract. [2023 Aug 1];11(8):2302–2308. doi: 10.1016/j.jaip.2023.02.022
   PubMed Web of Science ®Google Scholar
• Gimenez-Arnau AM, Podder I. Current perspectives and future directions in the management of chronic spontaneous urticaria and their link to disease pathogenesis and biomarkers. Ital J Dermatol Venerol. [2023 Aug 1];158(4):302–315. doi: 10.23736/S2784-8671.23.07537-0
   PubMedGoogle Scholar
• Gimenez-Arnau AM, Manzanares N, Podder I. Recent updates in urticaria. Med Clin. [2023 Nov 24];161(10):435–444. doi: 10.1016/j.medcli.2023.06.026
   PubMed Web of Science ®Google Scholar
• Kay AB, Clark P, Maurer M, et al. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol. 2015;172(5):1294–1302. doi: 10.1111/bjd.13621
   PubMed Web of Science ®Google Scholar
• Wedi B. Emerging treatments for chronic urticaria. Expert Opin Investig Drugs. [2022 Mar 1];31(3):281–290. doi: 10.1080/13543784.2022.2042513
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. [2009 Oct 1];64(10):1427–1443. doi: 10.1111/j.1398-9995.2009.02178.x
   PubMed Web of Science ®Google Scholar
• Staubach P, Peveling-Oberhag A, Lang BM, et al. Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review. J DermatolTreat. [2022 Mar 1];33(2):1119–1122. doi: 10.1080/09546634.2020.1782326
   Google Scholar
• Chang J, Cattelan L, Ben-Shoshan M, et al. Management of pediatric chronic spontaneous urticaria: a review of Current evidence and guidelines. J Asthma Allergy. [2021 Mar 9];14:187–199. doi: 10.2147/JAA.S249765
   PubMed Web of Science ®Google Scholar
• Maurer M, Khan DA, Elieh Ali Komi D, et al. Biologics for the use in chronic spontaneous urticaria: when and which. J Allergy Clin Immunol Pract. [2021 Mar 1];9(3):1067–1078. doi: 10.1016/j.jaip.2020.11.043
   PubMed Web of Science ®Google Scholar
• Wedi B, Traidl S. Anti-IgE for the treatment of chronic urticaria. Immunotargets Ther. 2021;Feb 17;10:27–45. doi: 10.2147/ITT.S261416
   PubMed Web of Science ®Google Scholar
• Urgert MC, van den Elzen MT, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. [2015 Aug 1];173(2):404–415. doi: 10.1111/bjd.13845
   PubMed Web of Science ®Google Scholar
• Zhao Z, Ji C, Yu W, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. [2016 Jun 1];137(6):1742–1750.e4. doi: 10.1016/j.jaci.2015.12.1342
   PubMed Web of Science ®Google Scholar
• Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy. [2021 Jan 1];76(1):59–70. doi: 10.1111/all.14547
   PubMed Web of Science ®Google Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. [2019 Jan 1];155(1):29–38. doi: 10.1001/jamadermatol.2018.3447
   PubMed Web of Science ®Google Scholar
• Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. [2020 Nov 1];37(6):1051–1054. doi: 10.1111/pde.14360
   PubMed Web of Science ®Google Scholar
• Passanisi S, Arasi S, Caminiti L, et al. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. [2020 Jul 1];33(4):e13489. doi: 10.1111/dth.13489
   PubMed Web of Science ®Google Scholar
• Al-Shaikhly T, Rosenthal JA, Ayars AG, et al. Omalizumab for chronic urticaria in children younger than 12 years. Ann Allergy Asthma Immunol. [2019 Aug 1];123(2):208–210.e2. doi: 10.1016/j.anai.2019.05.003
   PubMed Web of Science ®Google Scholar
• Netchiporouk E, Nguyen CH, Thuraisingham T, et al. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol. [2015 Sep 1];26(6):585–588. doi: 10.1111/pai.12407
   PubMed Web of Science ®Google Scholar
• Wedi B. Ligelizumab for the treatment of chronic spontaneous urticaria. Expert Opin Biol Ther. [2020 Aug 1];20(8):853–861. doi: 10.1080/14712598.2020.1767061
   PubMed Web of Science ®Google Scholar
• Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. [2020 Jan 8];11(1):165–w. doi: 10.1038/s41467-019-13815-w
   PubMed Web of Science ®Google Scholar
• Maurer M, Ensina LF, Gimenez-Arnau AM, et al. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. [2024 Jan 13];403(10422):147–159. doi: 10.1016/S0140-6736(23)01684-7
   PubMed Web of Science ®Google Scholar
• Staubach P, Alvaro-Lozano M, Sekerel BE, et al. Ligelizumab in adolescents with chronic spontaneous urticaria: results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis. Pediatr Allergy Immunol. [2023 Jul 1];34(7):e13982. doi: 10.1111/pai.13982
   PubMed Web of Science ®Google Scholar
• Saini S, Grattan C, Kim S, et al. Efficacy and safety of ct-p39 compared to reference omalizumab in patients with chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2023;131(5, Supplement 1):S34. doi: 10.1016/j.anai.2023.08.112
   Web of Science ®Google Scholar
• Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. [2024 Feb 29]. doi: 10.1016/j.jaci.2024.01.028
   Google Scholar
• Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. [2022 Sep 17];400(10356):908–919. doi: 10.1016/S0140-6736(22)01539-2
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. [2021 Dec 9];385(24):2230–2240. doi: 10.1056/NEJMoa2106567
   PubMed Web of Science ®Google Scholar
• Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. [2022 Dec 22];387(25):2317–2330. doi: 10.1056/NEJMoa2205982
   PubMed Web of Science ®Google Scholar
• Nieto Garcia A, Garriga-Baraut T, Plaza Martin AM, et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Pediatr Allergy Immunol. [2021 Jul 1];32(5):980–991. doi: 10.1111/pai.13484
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh H, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. [2013 Mar 7];368(10):924–935. doi: 10.1056/NEJMoa1215372
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. [2015 Jan 1];135(1):67–75. doi: 10.1038/jid.2014.306
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. [2013 Jul 1];132(1):101–109. doi: 10.1016/j.jaci.2013.05.013
   PubMed Web of Science ®Google Scholar
• Balp M, Weller K, Carboni V, et al. Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol. [2018 Sep 1];29(6):630–636. doi: 10.1111/pai.12910
   PubMedGoogle Scholar